Research programme: EVade ribonucleases - Quintessence Biosciences

Drug Profile

Research programme: EVade ribonucleases - Quintessence Biosciences

Alternative Names: PEG-RNases - Quintessence; QBI-206

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Quintessence Biosciences
  • Class Ribonucleases
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • Research Immunological disorders; Inflammation

Most Recent Events

  • 20 Oct 2016 EVade ribonucleases are available for partnering as of 20 Oct 2016.
  • 20 Oct 2016 Early research in Immunological disorders in USA (unspecified route)
  • 20 Oct 2016 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top